SE8102193L - Terapeutiskt aktiv organisk forening och dess anvendning - Google Patents

Terapeutiskt aktiv organisk forening och dess anvendning

Info

Publication number
SE8102193L
SE8102193L SE8102193A SE8102193A SE8102193L SE 8102193 L SE8102193 L SE 8102193L SE 8102193 A SE8102193 A SE 8102193A SE 8102193 A SE8102193 A SE 8102193A SE 8102193 L SE8102193 L SE 8102193L
Authority
SE
Sweden
Prior art keywords
sec
compound
bound
active organic
group
Prior art date
Application number
SE8102193A
Other languages
English (en)
Inventor
J P E Carlsson
R E A V Axen
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to SE8102193A priority Critical patent/SE8102193L/sv
Priority to EP82850071A priority patent/EP0064040B1/en
Priority to JP57501179A priority patent/JPH0662634B2/ja
Priority to DE8282850071T priority patent/DE3265744D1/de
Priority to PCT/SE1982/000109 priority patent/WO1982003395A1/en
Publication of SE8102193L publication Critical patent/SE8102193L/sv
Priority to US06/728,392 priority patent/US5124441A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/70—Sulfur atoms
    • C07D277/76—Sulfur atoms attached to a second hetero atom
    • C07D277/78—Sulfur atoms attached to a second hetero atom to a second sulphur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
SE8102193A 1981-04-06 1981-04-06 Terapeutiskt aktiv organisk forening och dess anvendning SE8102193L (sv)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE8102193A SE8102193L (sv) 1981-04-06 1981-04-06 Terapeutiskt aktiv organisk forening och dess anvendning
EP82850071A EP0064040B1 (en) 1981-04-06 1982-04-05 Therapeutically active disulphide compounds and their use
JP57501179A JPH0662634B2 (ja) 1981-04-06 1982-04-05 治療上活性な化合物
DE8282850071T DE3265744D1 (en) 1981-04-06 1982-04-05 Therapeutically active disulphide compounds and their use
PCT/SE1982/000109 WO1982003395A1 (en) 1981-04-06 1982-04-05 Therapeutically active compound and pharmaceutical composition containing the same
US06/728,392 US5124441A (en) 1981-04-06 1985-04-29 Therapeutically active compound and its use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8102193A SE8102193L (sv) 1981-04-06 1981-04-06 Terapeutiskt aktiv organisk forening och dess anvendning

Publications (1)

Publication Number Publication Date
SE8102193L true SE8102193L (sv) 1982-10-07

Family

ID=20343534

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8102193A SE8102193L (sv) 1981-04-06 1981-04-06 Terapeutiskt aktiv organisk forening och dess anvendning

Country Status (6)

Country Link
US (1) US5124441A (sv)
EP (1) EP0064040B1 (sv)
JP (1) JPH0662634B2 (sv)
DE (1) DE3265744D1 (sv)
SE (1) SE8102193L (sv)
WO (1) WO1982003395A1 (sv)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2522269A1 (fr) * 1982-02-26 1983-09-02 Pasteur Institut Agents antitumoraux, tels que la daunorubicine, a efficacite amelioree, leur obtention et procede pour augmenter l'efficacite des agents antitumoraux
JPS5937708U (ja) * 1982-08-31 1984-03-09 日本電気ホームエレクトロニクス株式会社 スライド制御部品取付け装置
SE8302758L (sv) * 1983-05-17 1984-11-18 Pharmacia Ab Sett for uppspjelkning av disulfidbindningar och derigenom erhallen forening
FR2551442B1 (fr) * 1983-09-05 1987-04-30 Centre Nat Rech Scient Nouveaux derives furaniques, leur preparation et leur application
GB8334499D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Derivatives
DE3887691T2 (de) * 1987-11-10 1994-06-09 Upjohn Co Cephalosporin-antibiotika.
US5223496A (en) * 1987-11-10 1993-06-29 The Upjohn Company Cephalosporin antibiotics
FI102355B1 (sv) * 1988-02-11 1998-11-30 Bristol Myers Squibb Co Förfarande för framställning av antracyklinimmunokonjugat med en sammanbindande länk
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6677309B1 (en) 1997-04-11 2004-01-13 University Technology Corporation Anti-cancer drug aldehyde conjugate drugs with enhanced cytotoxicity compounds, compositions and methods
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1317452B1 (en) * 2000-09-15 2006-05-17 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6653301B2 (en) 2000-12-21 2003-11-25 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MXPA04007697A (es) * 2002-02-06 2004-11-10 Vertex Pharma Compuestos de heteroarilo utiles como inhibidores de gsk-3.
AU2003218215A1 (en) * 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CN1319968C (zh) * 2002-08-02 2007-06-06 沃泰克斯药物股份有限公司 用作gsk－3的抑制剂的吡唑组合物
US7601718B2 (en) * 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
EP1694671A2 (en) * 2003-12-04 2006-08-30 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
US7282590B2 (en) * 2004-02-12 2007-10-16 The Research Foundation Of State University Of New York Drug conjugates
US7737151B2 (en) * 2005-08-18 2010-06-15 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
ES2533241T3 (es) * 2005-11-03 2015-04-08 Vertex Pharmaceuticals Incorporated Aminopirimidinas útiles como inhibidores de cinasas
EP2086965B1 (en) * 2006-11-02 2010-02-10 Vertex Pharmaceuticals, Inc. Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
WO2008077086A1 (en) * 2006-12-19 2008-06-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
NZ579483A (en) 2007-03-09 2012-07-27 Vertex Pharma Aminopyridines useful as inhibitors of protein kinases
JP5520057B2 (ja) * 2007-03-09 2014-06-11 バーテックス ファーマシューティカルズ インコーポレイテッド 蛋白キナーゼの阻害剤として有用なアミノピリミジン
WO2008112651A2 (en) * 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
CA2683785A1 (en) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
CN101679387A (zh) * 2007-05-02 2010-03-24 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶类化合物
MX2009011810A (es) 2007-05-02 2010-01-14 Vertex Pharma Tiazoles y pirazoles utiles como inhibidores de cinasa.
EP2152696B1 (en) * 2007-05-02 2014-09-24 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
WO2008147626A2 (en) * 2007-05-24 2008-12-04 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
AU2008282156B2 (en) * 2007-07-31 2014-07-17 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
CN102215816A (zh) * 2008-09-03 2011-10-12 沃泰克斯药物股份有限公司 共晶和包含所述共晶的药物制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36587A (en) * 1970-05-05 1977-10-31 Grassetti D Compositions containing pyridine derivatives and their use in a method of modifying cellular surface reactions
US4049665A (en) * 1975-12-24 1977-09-20 Colgate-Palmolive Company Unsymmetrical disulfides as antimicrobial agents
SE430062B (sv) * 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
SE431758B (sv) * 1977-03-04 1984-02-27 Pharmacia Fine Chemicals Ab Som tioleringsreagens eller berarmatris for enzymer anvendbart derivat av en sh-grupphaltig polymer
SE427505B (sv) * 1977-03-04 1983-04-11 Pharmacia Diagnostics Ab Reagens till anvendning vid immunkemiska bestemningsmetoder
FR2434392A1 (fr) * 1978-04-28 1980-03-21 Toyo Jozo Kk Nouveau compose disulfure utile dans la chromatographie de covalence
FR2430943A1 (fr) * 1978-07-13 1980-02-08 Toyo Jozo Kk Nouveaux derives disulfures
JPS6058232B2 (ja) * 1978-07-13 1985-12-19 東洋醸造株式会社 新規なジスルフイド誘導体
JPS5522657A (en) * 1978-12-28 1980-02-18 Toyo Jozo Co Ltd Reactive compound
US4258193A (en) * 1978-07-13 1981-03-24 Toyo Jozo Kabushiki Kaisha Disulfide derivatives having S--S exchange reactivity
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
SE446184B (sv) * 1979-01-12 1986-08-18 Toyo Jozo Kk Polyfunktionell disulfidforening anvendbar som tverbindande medel
FR2470773B1 (sv) * 1979-11-28 1983-01-28 Pasteur Institut
JPS5686121A (en) * 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation

Also Published As

Publication number Publication date
WO1982003395A1 (en) 1982-10-14
JPS58500480A (ja) 1983-03-31
EP0064040A1 (en) 1982-11-03
US5124441A (en) 1992-06-23
JPH0662634B2 (ja) 1994-08-17
EP0064040B1 (en) 1985-08-28
DE3265744D1 (en) 1985-10-03

Similar Documents

Publication Publication Date Title
SE8102193L (sv) Terapeutiskt aktiv organisk forening och dess anvendning
SE8102194L (sv) Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna
DK0430045T3 (da) Ascorbinsyretocopherylphosphatdiestere til hæmning af Maillards reaktion
NO842978L (no) Farmasoeytiske midler for behandling av diabetes
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
ATE83659T1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
AU549481B2 (en) Hair growing agent
SE8403487L (sv) Farmaceutisk komposition
NO890259L (no) Fremgangsmaate for fremstilling av terapeutisk aktive etylfenoksyacetamider.
EP0444196A4 (en) Agent for treatment and prophylaxis of ischemic disease of heart or brain
DE3764724D1 (de) 2-phenylbenzoxepin-derivat.
DE69122364D1 (de) Verwendung von (S)-Isofluran und (S)-Desfluran zur Anästhesie sowie entsprechende Arzneimittelzubereitungen
FR2585572B3 (fr) Nouvelles compositions pharmaceutiques a base d'un sel de l'acide p. chlorophenoxyacetique destinees au traitement des neuropathies et assurant la regeneration nerveuse
DE68904462D1 (de) 4-chinolincarbonsaeure-derivate, brauchbar zur behandlung von haut- und muco-epithelial-gewebekrankheiten.
DE69501359D1 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
HUT57204A (en) Process for producing 4-fluoro-2-///4-methoxy-2-pyridinyl/-methyl/-sulfinyl/-1h-benzimidazol with gastric acid secration-diminishing activity and pharmaceutical compositions containing them
ATE80616T1 (de) Prostaglandin e1-derivate und ihre therapeutische anwendung.
ATE126061T1 (de) Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.
DK552985A (da) Mercaptanderivater, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende samme
DE69007065T2 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
DE3778642D1 (de) Therapeutikum zur behandlung von magengeschwueren.
ATE108331T1 (de) Verwendung von tnf zur herstellung eines arzneimittels zur behandlung von psoriasis.
ATE106732T1 (de) Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
DK277387A (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
ATE24834T1 (de) Verwendung von beta-(1-adamantyl)-alpha, alphadimethylethylamin zur herstellung eines arzneimittels zur behandlung von otitis externa bei hunden.

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 8102193-3

Effective date: 19860929

Format of ref document f/p: F